Tandem Investment Advisors Inc. Invests $217,000 in Revvity, Inc. (NYSE:RVTY)

Tandem Investment Advisors Inc. acquired a new position in shares of Revvity, Inc. (NYSE:RVTY) during the fourth quarter, HoldingsChannel reports. The firm acquired 1,983 shares of the company’s stock, valued at approximately $217,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. acquired a new position in shares of Revvity during the 3rd quarter worth approximately $1,579,487,000. Ceredex Value Advisors LLC acquired a new position in shares of Revvity during the 4th quarter worth approximately $108,353,000. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Revvity during the 4th quarter worth approximately $33,568,000. Boston Trust Walden Corp acquired a new position in shares of Revvity during the 4th quarter worth approximately $25,154,000. Finally, KBC Group NV acquired a new position in shares of Revvity during the 3rd quarter worth approximately $25,301,000. Institutional investors own 86.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RVTY. Raymond James boosted their target price on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus boosted their target price on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. KeyCorp upped their price objective on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a report on Friday, February 2nd. Wells Fargo & Company began coverage on Revvity in a report on Tuesday, December 19th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Finally, Barclays upped their price objective on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Revvity has a consensus rating of “Moderate Buy” and an average target price of $118.91.

Revvity Price Performance

Shares of NYSE RVTY traded up $0.26 during mid-day trading on Wednesday, reaching $100.54. The company had a trading volume of 773,236 shares, compared to its average volume of 861,356. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07. Revvity, Inc. has a one year low of $79.50 and a one year high of $136.89. The firm has a market cap of $12.42 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 2.66 and a beta of 1.09. The business’s 50-day simple moving average is $104.96 and its 200 day simple moving average is $101.71.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The company had revenue of $695.90 million for the quarter. On average, research analysts predict that Revvity, Inc. will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Thursday, April 18th. Revvity’s payout ratio is currently 5.09%.

Insider Buying and Selling

In related news, insider Prahlad R. Singh sold 21,217 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.60% of the stock is owned by company insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.